by Eric Christianson | Mar 8, 2026 | Endocrine Medication and Disease State Clinical Pearls
Diabetes management can be quite complex as it is a progressive disease, and goals can change depending on a variety of patient factors. In general, the ADA suggests an A1C goal of <7%, but in some cases, less stringent goals like <8% may be appropriate. The...
by Eric Christianson | Jul 16, 2025 | Polypharmacy Cases And The Prescribing Cascade
Counteracting drug effects are all too common in geriatric and polypharmacy patients. I wanted to share common examples that I’ve seen in my practice as a clinical pharmacist. NSAIDs vs. AntihypertensivesCase: A 68-year-old man with hypertension controlled on...
by Eric Christianson | Jun 15, 2025 | Endocrine Case Studies
One of my biggest pet peeves is the use of sulfonylureas with insulin. Recall that sulfonylureas stimulate the release of insulin and in many patients with Type 2 diabetes we may not be getting much out of the sulfonylurea or in some cases, the extra boost in insulin...
by Eric Christianson | Jan 26, 2025 | Endocrine Medication and Disease State Clinical Pearls
Type II diabetes is a complicated disease state that often requires a combination of medications to control. However, some combinations of antidiabetes medications, such as sulfonylureas and basal insulin, may lead to unintended adverse effects. In this article, we...
by Eric Christianson | Mar 10, 2024 | Endocrine Medication and Disease State Clinical Pearls
For individuals with type 2 diabetes taking insulin, managing doses is a critical aspect of their treatment regimen. Proper management of insulin doses can help maintain blood sugar levels within a healthy range and prevent complications associated with high or low...
